Gennev Safety, Regulation & Compliance Posture: An Independent Review

What Gennev Actually Is

Gennev is a direct-to-consumer telehealth company that specializes in menopause and perimenopause care. Its core service connects patients with clinicians who have training in menopausal medicine for virtual consultations, symptom assessment, and prescription management. The platform also sells a line of branded supplements, though these fall outside FDA drug regulation.

The company was founded in 2019 and acquired by Unified Women's Healthcare in 2022, giving it access to a larger clinical network. Approximately 1.1 million women enter menopause each year in the United States, and surveys suggest that up to 75% of women experience vasomotor symptoms such as hot flashes and night sweats [1]. The Menopause Society's 2022 Position Statement notes that "hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM)" [2]. Gennev's clinical model centers on this evidence base.

One distinction worth noting: Gennev positions itself as a menopause specialty platform rather than a general telehealth service. This vertical focus means its clinicians are expected to have specific training in hormonal management for midlife women, a domain that many primary care physicians receive limited education in during residency. A 2021 survey published in Menopause found that only 31.3% of OB/GYN residency programs included a menopause medicine curriculum [3].

Regulatory Framework and State Licensing

Gennev operates under the same regulatory structure that governs all U.S. telehealth prescribers. Each clinician must hold an active, unrestricted medical license in the state where the patient is located at the time of the consultation. This is not a Gennev-specific requirement. It is federal and state law.

State medical boards retain full disciplinary authority over providers who practice via telehealth. If a Gennev clinician prescribes inappropriately or fails to meet the standard of care, the relevant state board can investigate, sanction, or revoke that provider's license. The Federation of State Medical Boards (FSMB) has published model policy on telehealth that most states have adopted in some form, requiring an adequate patient-provider relationship before prescribing.

After the COVID-era telehealth flexibilities began sunsetting, the DEA finalized rules requiring an in-person evaluation for Schedule II-V controlled substances prescribed via telehealth. Hormone therapy products like estradiol and progesterone are not scheduled controlled substances under the Controlled Substances Act, so these DEA restrictions do not apply to the majority of Gennev's prescribing. Testosterone, which some menopause providers prescribe off-label for low libido, is a Schedule III controlled substance and would require compliance with DEA telehealth prescribing rules [4].

HIPAA Compliance and Data Handling

Telehealth platforms that handle protected health information (PHI) must comply with the Health Insurance Portability and Accountability Act. This is not optional. Gennev states that it uses HIPAA-compliant technology infrastructure for video visits, messaging, and medical records storage.

HIPAA compliance requires several concrete technical and administrative safeguards: encryption of data in transit and at rest, access controls limiting who can view patient records, audit logging, business associate agreements (BAAs) with third-party vendors, and workforce training on privacy practices [5]. The U.S. Department of Health and Human Services Office for Civil Rights enforces these requirements and publishes breach notifications when companies fail.

No HIPAA breach involving Gennev appears in the HHS Breach Portal as of this review. That is a factual observation, not a guarantee of future compliance. Patients should verify that any telehealth platform they use has a published Notice of Privacy Practices and can confirm its BAA structure upon request.

Prescribing Practices: What Gennev Clinicians Can and Cannot Prescribe

Gennev clinicians prescribe FDA-approved hormone therapy formulations, non-hormonal prescription alternatives, and make supplement recommendations. The prescribing scope aligns with what a board-certified OB/GYN or internist could prescribe in a traditional office visit.

FDA-approved hormone therapy options commonly prescribed through menopause telehealth include:

• Oral estradiol (0.5 mg, 1 mg, 2 mg tablets)
• Transdermal estradiol patches (0.025 mg to 0.1 mg per day)
• Micronized progesterone (Prometrium, 100 mg or 200 mg capsules)
• Combination estrogen-progestogen products
• Low-dose vaginal estrogen for GSM (creams, rings, tablets)

The Women's Health Initiative (WHI), which enrolled 27,347 postmenopausal women aged 50 to 79, established the risk-benefit framework that modern HRT prescribing follows. The estrogen-plus-progestogen arm showed a hazard ratio of 1.26 for invasive breast cancer (95% CI 1.00 to 1.59) over 5.6 years of follow-up [6]. Subsequent reanalysis demonstrated that for women aged 50 to 59 who initiated HRT within 10 years of menopause onset, the cardiovascular risk profile was neutral to favorable, with a hazard ratio for coronary heart disease of 0.76 (95% CI 0.50 to 1.16) [7].

Non-hormonal alternatives available through menopause telehealth include fezolinetant (Veozah), the first neurokinin-3 receptor antagonist approved by the FDA for moderate-to-severe VMS. In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg reduced moderate-to-severe hot flash frequency by 61.3% at week 12 compared to 42.4% for placebo [8]. Paroxetine 7.5 mg (Brisdelle) remains the only SSRI with FDA approval specifically for VMS. Gabapentin and clonidine are also prescribed off-label.

Dr. Stephanie Faubion, medical director of The Menopause Society, has stated: "The decision to use hormone therapy should be individualized based on a woman's symptoms, health history, and personal preferences, using the lowest effective dose for the shortest duration consistent with treatment goals" [2].

Clinical Guidelines Gennev Should Follow

Any menopause provider operating within the standard of care should align with at least two major clinical guidelines. The first is The Menopause Society's 2022 Hormone Therapy Position Statement, which recommends initiating HRT in symptomatic women who are within 10 years of menopause onset or under age 60, absent contraindications [2]. The second is the Endocrine Society's 2015 Clinical Practice Guideline on the treatment of symptoms of menopause, which provides similar age-window recommendations and emphasizes transdermal estradiol for women with elevated cardiovascular or thromboembolic risk [9].

Contraindications to systemic hormone therapy, per both guidelines, include:

• Undiagnosed abnormal uterine bleeding
• Active or history of breast cancer
• Active liver disease
• History of venous thromboembolism (for oral estrogen specifically)
• Known or suspected pregnancy
• Coronary heart disease or stroke (relative contraindication for initiation)

A telehealth platform's safety depends on whether its intake process screens for these contraindications before prescribing. Gennev's intake questionnaire asks about medical history, current medications, and cancer history. The adequacy of this screening depends on the individual clinician's judgment and follow-up questioning during the consultation.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141 reaffirms that "for women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms" [10].

Gennev Supplements: A Different Regulatory Category

Gennev sells branded supplement products marketed for menopause symptom relief. These products are regulated as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994, not as drugs. This distinction matters. The FDA does not require pre-market approval of dietary supplements for safety or efficacy [11]. Manufacturers are responsible for ensuring their products are safe before marketing, but the FDA does not verify those claims before the product reaches consumers.

This is not unique to Gennev. It applies to every supplement company in the United States. The practical implication is that when Gennev recommends a supplement alongside or instead of FDA-approved medications, patients should understand they are dealing with two fundamentally different evidence standards. An FDA-approved drug like estradiol has undergone Phase I through Phase III clinical trials involving thousands of participants. A supplement containing, for example, ashwagandha or black cohosh has not cleared that same regulatory bar.

A Cochrane review of black cohosh for menopausal symptoms, analyzing 16 randomized controlled trials with 2,027 participants, concluded there was "insufficient evidence from these trials for or against the use of black cohosh for menopausal symptoms" [12].

Patients should ask their Gennev clinician to distinguish between evidence-backed prescription recommendations and supplement suggestions that rest on a thinner evidence base.

How Gennev Compares to Alternative Menopause Telehealth Platforms

Several telehealth platforms now compete in the menopause space, including Midi Health, Evernow, and Alloy Health. A fair comparison requires looking at multiple dimensions.

Provider credentialing. Gennev, Midi, and Evernow all state they employ or contract with board-certified clinicians. The specificity of menopause training varies. Midi Health has publicly stated that its providers complete a proprietary menopause training program. Gennev emphasizes that its clinicians have menopause-focused expertise, though the exact training requirements are not publicly detailed.

Prescribing range. All four platforms prescribe FDA-approved HRT. Evernow has historically focused on a narrower formulary. Alloy Health offers both prescription HRT and non-prescription products. Gennev's hybrid model of prescription medications plus branded supplements is similar to Alloy's approach.

Insurance acceptance. Gennev accepts some insurance plans, which distinguishes it from cash-only competitors. Midi Health also accepts insurance. Evernow has historically operated on a subscription cash-pay model. Out-of-pocket costs for menopause telehealth visits range from approximately $75 to $350 per consultation depending on the platform and plan.

Lab work. Menopause is a clinical diagnosis based on symptoms and age, not hormone levels, per The Menopause Society [2]. However, some patients and providers prefer baseline labs. The availability and integration of lab ordering varies across platforms.

No head-to-head clinical trials compare outcomes between these platforms. The safety of any menopause telehealth service depends primarily on the individual clinician's adherence to established guidelines, not the brand name on the platform.

Red Flags Patients Should Watch For

Whether using Gennev or any menopause telehealth service, patients should watch for warning signs that a provider may not be practicing within evidence-based guidelines.

Prescribing systemic HRT to a woman over 60 or more than 10 years past menopause onset without a documented risk-benefit discussion violates current guideline recommendations [2] [9]. Recommending compounded bioidentical hormones as "safer" than FDA-approved bioidentical hormones misrepresents the evidence. The FDA, The Menopause Society, and the Endocrine Society have all stated that compounded hormones are not proven equivalent to FDA-approved products in safety or efficacy [13]. Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the WHI, has noted: "FDA-approved bioidentical hormones are available and should be used in preference to compounded preparations whenever possible" [7].

Failing to ask about breast cancer history, VTE history, or liver disease before prescribing oral estrogen is a clear safety gap. Recommending supplements as replacements for FDA-approved medications in women with moderate-to-severe VMS without disclosing the evidence gap is a transparency concern.

The Bottom Line on Gennev's Safety Profile

Gennev operates within the same legal and regulatory framework as any licensed telehealth prescriber in the United States. Its clinicians are subject to state medical board oversight, its platform claims HIPAA-compliant data handling, and its prescribing scope covers FDA-approved menopause medications. The platform's integration of supplements alongside prescription care introduces a category of products with lower regulatory scrutiny, and patients should treat those recommendations accordingly. According to a nationally representative CDC analysis, about 55.7% of women aged 40 to 65 reported receiving no treatment for their menopause symptoms [14]. For women in that group who have vasomotor symptoms meeting clinical treatment thresholds, a telehealth platform that follows published guidelines and prescribes FDA-approved therapies represents a reasonable access point, provided the individual clinician performs adequate screening and monitoring.